Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes.

Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled.

Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors.

This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus, Prof. P. Billiald and Dr. C. Gachet. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France and the prize for Innovation from SGAM (Société Générale Asset Management).